Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · mng-umap@100

MNG682

—

2f48483e-dafa-576a-9db0-23d83cb63049

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • CHOLESTEROL_HOMEOSTASIS+0.434
  • HEDGEHOG_SIGNALING+0.258
  • HEME_METABOLISM+0.238
  • ANDROGEN_RESPONSE+0.192
  • PEROXISOME+0.192
  • ADIPOGENESIS+0.170
  • ESTROGEN_RESPONSE_EARLY+0.164
  • OXIDATIVE_PHOSPHORYLATION+0.164
  • ESTROGEN_RESPONSE_LATE+0.127
  • BILE_ACID_METABOLISM+0.121

Top 10 suppressed

  • E2F_TARGETS-0.427
  • INTERFERON_GAMMA_RESPONSE-0.407
  • INTERFERON_ALPHA_RESPONSE-0.395
  • ALLOGRAFT_REJECTION-0.376
  • IL6_JAK_STAT3_SIGNALING-0.350
  • EPITHELIAL_MESENCHYMAL_TRANSITION-0.345
  • G2M_CHECKPOINT-0.336
  • INFLAMMATORY_RESPONSE-0.325
  • PANCREAS_BETA_CELLS-0.204
  • KRAS_SIGNALING_UP-0.184

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1MNG124
mng-umap@100
——0.836
29f9dec84-0c2c-4f85-8024-b8fb1de1eb81
colon-landscapes@1
——0.829
3MNG123
mng-umap@100
——0.818
4MNG1056
mng-umap@100
——0.776
5SRR8613741
breast-umap@18
—F0.776
6TCGA-44-6776-01A-11R-1858-07
lung-landscapes@6
—cohortA20.773
7MNG772
mng-umap@100
——0.769
8TCGA-A1-A0SQ-01A-21R-A144-07
breast-umap@18
—B0.768
9MNG1264
mng-umap@100
——0.768
10TCGA-78-7633-01A-11R-2066-07
lung-landscapes@6
—cohortA20.749

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 24 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
CHOLESTEROL_HOMEOSTASIS0.434Remibrutinib— uncovered
HEDGEHOG_SIGNALING0.258Inavolisib— uncovered
HEME_METABOLISM0.238Temsirolimus— uncovered
ANDROGEN_RESPONSE0.192Inavolisib— uncovered
PEROXISOME0.192Idelalisib— uncovered
ADIPOGENESIS0.170Inavolisib— uncovered
ESTROGEN_RESPONSE_EARLY0.164Inavolisib— uncovered
OXIDATIVE_PHOSPHORYLATION0.164Remibrutinib— uncovered
ESTROGEN_RESPONSE_LATE0.127Idelalisib— uncovered
BILE_ACID_METABOLISM0.121Inavolisib— uncovered
XENOBIOTIC_METABOLISM0.114Inavolisib— uncovered
NOTCH_SIGNALING0.111Inavolisib— uncovered
PI3K_AKT_MTOR_SIGNALING0.110Inavolisib— uncovered
PROTEIN_SECRETION0.082Remibrutinib— uncovered
APICAL_JUNCTION0.077Inavolisib— uncovered
APOPTOSIS0.077Idelalisib— uncovered
MITOTIC_SPINDLE0.077Inavolisib— uncovered
WNT_BETA_CATENIN_SIGNALING0.068Inavolisib— uncovered
KRAS_SIGNALING_DN0.059Remibrutinib— uncovered
FATTY_ACID_METABOLISM0.055Inavolisib— uncovered